Sectors
KRYS
Krystal Biotech, Inc.
312.58
1 x 311.72
2 x 314.96
bid
ask
+
2.27
0.73%
2 @ 07:10 AM
316.80 +4.22 (1.35%)
| Ytd | 26.79% | |
| 1y | 132.35% |
302.87
day range
317.21
122.80
52 week range
317.21
| Open | 309.53 | Prev Close | 310.31 | Low | 302.87 | High | 317.21 | Mkt Cap | 9.21B |
| Vol | 311.31K | Avg Vol | 303.92K | EPS | 7.47 | P/E | 41.84 | Forward P/E | 30.39 |
| Beta | 0.49 | Short Ratio | 12.24 | Inst. Own | 98.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 266.79 | 200-d Avg | 223.72 | 1yr Est | 318.22 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-04 | 2026-03 | 1.45 | 1.83 | 0.38 | 26.21% |
| 2026-02-17 | 2025-12 | 1.62 | N/A | N/A | N/A |
| 2026-02-17 | 2025-12 | 1.62 | 1.7 | 0.08 | 4.94% |
| 2025-11-03 | 2025-09 | 1.12 | N/A | N/A | N/A |
| 2025-11-03 | 2025-09 | 1.12 | 2.66 | 1.54 | 137.50% |
| 2025-08-04 | 2025-06 | 1.08 | 1.29 | 0.21 | 19.44% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-05 | Citigroup | Upgrade | Buy | Buy |
| 2026-05-05 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-03-27 | Wolfe Research | Upgrade | Peer Perform | |
| 2026-02-25 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-18 | Citigroup | Upgrade | Buy | Buy |
Profile
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-19 | GANGOLLI JULIAN S. | Director | 0.00 | Sale |
| 2026-02-26 | JANNEY DANIEL SPENCER | Director | 0.00 | Sale |
| 2026-03-03 | KRISHNAN KRISH S | Chief Executive Officer | 1.62M | Sale |
| 2026-03-03 | KRISHNAN SUMA M | Officer, Director and Beneficial Owner | 1.54M | Sale |
| 2026-03-01 | ROMANO KATHRYN | Officer | 22.37K | Sale |
| 2026-02-18 | ROSSI DINO A | Director | 78.69K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | FMR, LLC | 4.35M | 1.36B | 14.75% |
| 2025-12-30 | Blackrock Inc. | 3.94M | 1.23B | 13.36% |
| 2025-12-30 | Avoro Capital Advisors LLC | 2.89M | 903.01M | 9.80% |
| 2026-03-30 | Vanguard Portfolio Management LLC | 1.46M | 455.34M | 4.94% |
| 2025-12-30 | State Street Corporation | 1.34M | 419.58M | 4.55% |
| 2026-03-30 | Vanguard Capital Management LLC | 1.17M | 364.26M | 3.95% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.81M | 564.68M | 6.13% |
| 2026-03-30 | iShares Trust-iShares Core S&P Small-Cap ETF | 1.55M | 484.67M | 5.26% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 822.89K | 257.22M | 2.79% |
| 2026-03-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 785.53K | 245.54M | 2.66% |
| 2025-12-30 | SmallCap World Fund Inc | 752.24K | 235.14M | 2.55% |
| 2026-03-30 | iShares Trust-iShares Russell 2000 ETF | 600.77K | 187.79M | 2.04% |
